Finast: Clinically Proven 5α-Reductase Inhibition for Androgen-Related Conditions
Finast
| Product dosage: 1mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $2.02 | $121.00 (0%) | 🛒 Add to cart |
| 90 | $1.97 | $181.50 $177.00 (2%) | 🛒 Add to cart |
| 120 | $1.88 | $242.00 $225.00 (7%) | 🛒 Add to cart |
| 180 | $1.71 | $363.00 $308.00 (15%) | 🛒 Add to cart |
| 270 | $1.59
Best per pill | $544.50 $430.00 (21%) | 🛒 Add to cart |
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.60 | $78.00 (0%) | 🛒 Add to cart |
| 60 | $2.27 | $156.00 $136.00 (13%) | 🛒 Add to cart |
| 90 | $2.16 | $234.00 $194.00 (17%) | 🛒 Add to cart |
| 120 | $2.09 | $312.00 $251.00 (20%) | 🛒 Add to cart |
| 180 | $2.04 | $468.00 $367.00 (22%) | 🛒 Add to cart |
| 270 | $2.00
Best per pill | $702.00 $540.00 (23%) | 🛒 Add to cart |
Finast is a prescription medication containing the active ingredient finasteride, a selective inhibitor of type II 5α-reductase. This enzyme is responsible for the conversion of testosterone to dihydrotestosterone (DHT), a potent androgen implicated in the pathophysiology of benign prostatic hyperplasia (BPH) and androgenetic alopecia. By significantly reducing serum and scalp DHT concentrations, Finast addresses the underlying hormonal mechanism driving prostate enlargement and pattern hair loss in men. Its well-established efficacy and safety profile, demonstrated in large-scale clinical trials over decades, make it a cornerstone of pharmacological management for these conditions. Treatment requires appropriate medical supervision, adherence to prescribed dosing, and ongoing monitoring to ensure optimal therapeutic outcomes and management of potential adverse effects.
Features
- Contains 1mg or 5mg finasteride per tablet, allowing for condition-specific dosing
- Selective, competitive inhibition of type II 5α-reductase isoenzyme
- Reduces serum dihydrotestosterone (DHT) levels by approximately 70%
- Bioavailability of approximately 63%, unaffected by food
- Maximum plasma concentration reached within 1-2 hours post-administration
- Mean elimination half-life of approximately 6 hours in men aged 18-60
- Primarily metabolized via cytochrome P450 3A4 enzyme system
- Available in film-coated tablet formulation for ease of administration
- Demonstrated stability under recommended storage conditions
Benefits
- Significantly reduces prostate volume in patients with benign prostatic hyperplasia, improving urinary flow rates and reducing symptoms of obstruction
- Prevents further progression of male pattern hair loss (androgenetic alopecia) in the majority of treated patients
- Promotes hair regrowth in a substantial proportion of men with mild to moderate vertex baldness
- Reduces the risk of acute urinary retention and need for surgical intervention in BPH patients
- Provides continuous DHT suppression with once-daily dosing, maintaining consistent therapeutic effect
- Well-tolerated profile with most adverse effects being mild and reversible upon discontinuation
Common use
Finast is primarily prescribed for two distinct clinical indications in adult men. For the treatment of symptomatic benign prostatic hyperplasia, the 5mg formulation is administered to improve urinary flow, reduce symptoms of obstruction, and decrease the risk of disease progression. In the management of male pattern hair loss (androgenetic alopecia), the 1mg formulation is used to promote hair growth and prevent further hair loss on the vertex and anterior mid-scalp areas. Treatment response for BPH is typically evaluated within 6-12 months, while effects on hair growth may require 3-6 months of continuous therapy before becoming apparent and up to 2 years for maximal response. Continued treatment is necessary to sustain benefits, as discontinuation leads to reversal of effects within 12 months for BPH and gradual return to baseline hair loss patterns.
Dosage and direction
For the treatment of male pattern hair loss: One 1mg tablet taken orally once daily, with or without food. For the treatment of benign prostatic hyperplasia: One 5mg tablet taken orally once daily, with or without food. Tablets should be swallowed whole and not crushed or broken. Consistency in daily administration time is recommended to maintain stable plasma concentrations. For both indications, daily adherence is crucial for optimal therapeutic outcomes. Patients should be advised that clinical response may not be immediate, with BPH symptom improvement typically occurring within 2-4 weeks and maximal response at 6-12 months. Hair growth effects may require 3 months of continuous therapy before visible improvement and up to 2 years for maximal response. Dosage adjustment is not routinely required for elderly patients or those with renal impairment, but caution is advised in patients with hepatic impairment.
Precautions
Prior to initiating Finast therapy, a digital rectal examination (DRE) and appropriate diagnostic procedures should be performed to rule out prostate cancer, as Finast reduces PSA levels and may mask detection. Serum prostate-specific antigen (PSA) levels decrease by approximately 50% in patients with BPH after 6 months of therapy, and this reduction should be considered when interpreting PSA values for prostate cancer screening. Patients should be advised that Finast tablets should not be handled by women who are or may become pregnant due to risk of absorption through the skin and potential teratogenic effects. Caution is recommended in patients with hepatic impairment, as finasteride is extensively metabolized in the liver. Patients should be monitored for potential sexual side effects, which may include decreased libido, erectile dysfunction, and ejaculation disorders. Regular follow-up appointments are necessary to assess therapeutic response and monitor for adverse effects.
Contraindications
Finast is contraindicated in the following populations: women who are or may become pregnant due to the risk of abnormalities to external genitalia of a male fetus; pediatric patients; patients with hypersensitivity to finasteride or any component of the formulation; and women who are breastfeeding. The medication is specifically not indicated for use in women or children under any circumstances. Additionally, patients with demonstrated hypersensitivity reactions to other 5α-reductase inhibitors should avoid Finast. The 1mg formulation is contraindicated for treatment of BPH, while the 5mg formulation is contraindicated for treatment of hair loss, as these indications require specific dosing regimens validated through clinical trials.
Possible side effects
The most frequently reported adverse reactions associated with Finast therapy include sexual dysfunction manifestations: decreased libido (1.8-3.4% in BPH studies, 1.8% in hair loss studies), erectile dysfunction (4.9-8.1% in BPH studies, 1.3% in hair loss studies), and ejaculation disorders (1.7-3.7% in BPH studies, 0.8% in hair loss studies). These effects typically occur early in therapy, may decrease with continued treatment, and generally resolve upon discontinuation. Additional reported effects include breast tenderness and enlargement (0.5-2.2%), skin rash (0.5-1.1%), and hypersensitivity reactions including lip swelling and testicular pain. Post-marketing reports have included persistent sexual dysfunction after discontinuation, male infertility, depression, and breast cancer. Laboratory abnormalities may include decreased semen volume and total sperm count, though these parameters remain within normal range for most patients and generally recover after treatment cessation.
Drug interaction
Formal drug interaction studies have demonstrated no clinically significant interactions with antipyrine, digoxin, propranolol, theophylline, or warfarin. However, potential interactions may occur with medications that inhibit the cytochrome P450 3A4 enzyme system, such as ketoconazole, itraconazole, erythromycin, and protease inhibitors, which could increase finasteride exposure. Concurrent administration with other 5α-reductase inhibitors (dutasteride) is not recommended due to potential additive effects without established benefit. Although no interaction has been demonstrated with alpha-adrenergic blockers (tamsulosin, terazosin), caution is advised when used concomitantly for BPH treatment due to potential additive blood pressure effects. Finasteride does not appear to affect the pharmacokinetics of ethanol, antipyrine, or digoxin, but physicians should monitor patients for potential interactions with all concomitant medications.
Missed dose
If a dose of Finast is missed, patients should take it as soon as remembered unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed dose. Consistent daily administration is important for maintaining stable DHT suppression, but occasional missed doses are not expected to significantly impact long-term therapeutic outcomes. Patients should be educated about the importance of adherence and encouraged to establish a routine for daily administration. If multiple doses are missed, patients should contact their healthcare provider for guidance but generally should resume the regular once-daily dosing schedule without dose adjustment.
Overdose
In reported cases of overdose with finasteride, doses up to 400 mg daily have been administered with no associated adverse effects. Single doses up to 80 mg and multiple doses up to 240 mg/day for 10 days have been tolerated without observed toxicity. There is no specific antidote for finasteride overdose. Treatment should be symptomatic and supportive, with particular attention to potential cardiovascular effects due to the propylene glycol component in the formulation. Gastric lavage may be considered if ingestion occurred within a short time frame. Given finasteride’s high protein binding and extensive tissue distribution, dialysis is not likely to be beneficial. Patients should be monitored for potential adverse effects, particularly related to sexual function and mood, and managed supportively. Medical toxicology consultation is recommended in cases of significant overdose.
Storage
Finast tablets should be stored at controlled room temperature, 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F). Tablets should be kept in their original container with the lid tightly closed to protect from moisture and light. The medication should be kept out of reach of children and pets to prevent accidental ingestion. Unused medication should be properly disposed of according to local regulations, not flushed down toilets or drains. Patients should be advised to check expiration dates and not use medication beyond the printed expiration date. Tablets should be protected from excessive heat and humidity, and should not be stored in bathrooms or near kitchen sinks where moisture levels may be elevated.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Finast is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Patients should not initiate, adjust, or discontinue treatment without consulting their physician. The information provided here may not include all possible uses, directions, precautions, warnings, interactions, or adverse effects. Healthcare professionals should reference the full prescribing information for complete details. Actual patient experiences may vary, and individual responses to medication cannot be guaranteed. This product is not intended to diagnose, treat, cure, or prevent any disease. Patients should discuss their medical history and all current medications with their healthcare provider before starting treatment with Finast.
Reviews
Clinical studies involving over 9,000 patients have demonstrated Finast’s efficacy and safety profile. In randomized controlled trials for BPH, the 5mg dose significantly improved symptom scores (decrease of approximately 3.3 points vs 1.3 points with placebo on the AUA Symptom Index) and increased peak urinary flow rate (1.9 mL/sec vs 0.2 mL/sec with placebo). For androgenetic alopecia, studies showed that after 2 years of treatment, 66% of men taking 1mg finasteride experienced increased hair growth versus 7% with placebo, with 83% of treated patients showing no further hair loss compared to 28% with placebo. Long-term extension studies up to 10 years have demonstrated maintained efficacy with persistent DHT suppression. Patient-reported outcomes indicate high satisfaction with treatment results, particularly regarding improved urinary symptoms and hair growth maintenance, though some patients discontinue due to sexual side effects. Real-world evidence supports the clinical trial findings, showing sustained effectiveness in appropriate patient populations with proper medical supervision.